X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs FDC LTD. - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. FDC LTD. FRESENIUS KABI ONCO./
FDC LTD.
 
P/E (TTM) x 22.1 24.3 91.2% View Chart
P/BV x 3.1 4.8 64.4% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 FRESENIUS KABI ONCO.   FDC LTD.
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
FDC LTD.
Mar-14
FRESENIUS KABI ONCO./
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs176144 122.6%   
Low Rs7979 99.4%   
Sales per share (Unadj.) Rs37.747.6 79.2%  
Earnings per share (Unadj.) Rs5.17.6 66.9%  
Cash flow per share (Unadj.) Rs6.79.0 74.6%  
Dividends per share (Unadj.) Rs02.25 0.0%  
Dividend yield (eoy) %02.0 0.0%  
Book value per share (Unadj.) Rs42.547.5 89.5%  
Shares outstanding (eoy) m158.23177.83 89.0%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.42.3 144.4%   
Avg P/E ratio x25.014.6 170.9%  
P/CF ratio (eoy) x18.912.3 153.3%  
Price / Book Value ratio x3.02.3 127.8%  
Dividend payout %029.6 0.0%   
Avg Mkt Cap Rs m20,13519,784 101.8%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7031,221 57.6%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,9638,459 70.5%  
Other income Rs m18394 4.6%   
Total revenues Rs m5,9818,852 67.6%   
Gross profit Rs m1,4302,070 69.1%  
Depreciation Rs m258249 103.5%   
Interest Rs m-2631 -83.8%   
Profit before tax Rs m1,2162,184 55.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342606 56.5%   
Profit after tax Rs m8061,353 59.6%  
Gross profit margin %24.024.5 98.0%  
Effective tax rate %28.127.7 101.5%   
Net profit margin %13.516.0 84.5%  
BALANCE SHEET DATA
Current assets Rs m5,1024,355 117.1%   
Current liabilities Rs m2,3851,792 133.1%   
Net working cap to sales %45.630.3 150.3%  
Current ratio x2.12.4 88.0%  
Inventory Days Days15044 337.5%  
Debtors Days Days11325 459.3%  
Net fixed assets Rs m5,1483,025 170.2%   
Share capital Rs m158179 88.6%   
"Free" reserves Rs m6,5568,243 79.5%   
Net worth Rs m6,7328,453 79.6%   
Long term debt Rs m95211 8,899.1%   
Total assets Rs m10,38810,557 98.4%  
Interest coverage x-45.871.4 -64.1%   
Debt to equity ratio x0.10 11,174.4%  
Sales to assets ratio x0.60.8 71.6%   
Return on assets %7.513.1 57.3%  
Return on equity %12.016.0 74.8%  
Return on capital %14.623.5 62.1%  
Exports to sales %74.513.3 559.6%   
Imports to sales %24.83.3 741.0%   
Exports (fob) Rs m4,4411,126 394.5%   
Imports (cif) Rs m1,477283 522.4%   
Fx inflow Rs m5,2981,146 462.2%   
Fx outflow Rs m1,772355 498.8%   
Net fx Rs m3,525791 445.8%   
CASH FLOW
From Operations Rs m1,2741,485 85.8%  
From Investments Rs m-1,204-620 194.4%  
From Financial Activity Rs m-196-753 26.1%  
Net Cashflow Rs m-126113 -112.0%  

Share Holding

Indian Promoters % 0.0 68.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.7 6.4%  
FIIs % 9.6 7.5 128.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.0 47.9%  
Shareholders   42,599 23,730 179.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS